GovChime
Notice ID: 236b4401ef314a44b98aa9e74aab050dCombined Synopsis/Solicitation

Single Extracellular Vesicle Analysis from HANDLS participants.

Archived on August 21, 2024. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
12:00 PM UTC−04:00
Posted
July 30, 2024
Notice type
Combined Synopsis/Solicitation
NAICS
541380: Testing Laboratories and Services
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH NIDA
Last updated
Dec 4, 2025

Identifiers

Solicitation number
75N95024Q00482
Notice ID
236b4401ef314a44b98aa9e74aab050d

Description

NON-COMPETITIVE COMBINED SYNOPSIS / SOLICITATION Title: Single Extracellular Vesicle Analysis from HANDLS participants (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotations are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N95024Q00482 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13 Simplified Acquisition Procedures; and FAR Part 12 Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Nanometrix, LTD, 26 Stanley Road, Oxford, OX4 1QZ, United Kingdom for the Single Extracellular Vesicle Analysis from HANDLS participants. This acquisition is conducted as non-competitive for a commercial item or service and is conducted pursuant to FAR 13.106-1(b)(1). (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2024-05, with effective date 05/22/2024. (iv) The associated NAICS code is 541380 - Testing Laboratories and Services and the small business size standard is $19.0 million. This requirement is non-competitive with no set-aside restrictions. (v) This requirement is for the following services: Single Extracellular Vesicle Analysis from HANDLS participants. (vi) The DNA Repair Unit (DRU) hypothesizes that differences in extracellular vesicle (EV) morphology, size and cargo contribute to health disparities in age-related diseases. The DRU also hypothesizes that there will be different EV protein levels and morphology for participants who acquire chronic kidney disease in the HANDLS cohort. This analysis includes EV sample preparation and imaging on a Single-molecule localization microscopy (SMLM) system, computation of EV size and morphology, analysis the molecular profiles and differences of the EVs across different surfaces. The contractor will perform quality controls assessments. This specialized analysis is state of the art in the field and requires limited volumes of extracellular vesicles, which is critical since HANDLS plasma samples are limited and have high research significance. The contractor shall image and analyze plasma extracellular vesicles from 30 samples provided by the government. Specifically the contractor shall: EV surface capture TMIX (CD9 + CD81 + CD63) EV Sample imaging: EV sample preparation and imaging on an SMLM system EV size and morphological analysis: EV size distributions will be computed for each sub-population and morphologies EV quality assurance: Based on EV morphologies and noise signal produce a measure of quality of EVs EV population analysis: Analyze the molecular profiles and differences of the EVs across the different surfaces See Attachment 1 - Statement of Work. (vii) The Government anticipates award of a firm fixed-price purchase order for this acquisition, and the anticipated period of performance is 12 months ARO (After Receipt of Order). (viii) The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of provision) The following provisions apply to this acquisition and are incorporated by reference: FAR 52.204-7, System for Award Management (Oct 2018) FAR 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020) FAR 52.204-29, Federal Acquisition Supply Chain Security Act Orders Representation and Disclosures (Dec 2023) FAR 52.212-1, Instructions to Offerors-Commercial Products and Commercial Services (Sep 2023) FAR 52.212-3, Offeror Representations and Certifications-Commercial Products and Commercial Services (May 2024) HHSAR 352.239-73 Electronic and Information Technology Accessibility Notice (December 18, 2015) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of clause) The following clauses apply to this acquisition and are incorporated by reference: FAR 52.204-13, System for Award Management Maintenance (Oct 2018) FAR 52.204-18, Commercial and Government Entity Code Maintenance (Aug 2020) FAR 52.212-4, Contract Terms and Conditions-Commercial Products and Commercial Services (Nov 2023). Addendum to this FAR clause applies to this acquisition and is attached. HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015) HHSAR 352.239-74, Electronic and Information Technology Accessibility (December 18, 2015) The following provisions and clauses apply to this acquisition and are attached in full text. Offerors MUST complete the applicable provisions and submit completed copies as separate documents with their proposal. FAR 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Nov 2021) FAR 52.204-26, Covered Telecommunications Equipment or Services-Representation (Oct 2020) FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Products and Commercial Services (May 2024) FAR 52.222-52, Exemption from Application of the Service Contract Labor Standards to Contracts for Certain Services-Certification (May 2014) NIH Invoice and Payment Provisions (Mar 2023) (ix) The Government will evaluate quotations or offers in accordance with FAR 13.106-2 and award a purchase order from this solicitation to the responsible offeror whose quote conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate quotes: a. Technical capability of the item offered to meet the Government requirement; b. Price; and c. Past performance [see FAR 13.106-2(b)(3)]. (x) Offerors must include a completed copy of the provision at FAR 52.212-3, Offeror Representations and Certifications-Commercial Items (May 2024), with its offer. If the offeror has completed FAR clause 52.212-3 at www.sam.gov, then the offeror does not need to provide a completed copy with its offer. (xi) There are no additional contract requirement(s) or terms and conditions applicable to this acquisition. (xii) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xiii) Responses to this solicitation must include clear and convincing evidence of the offerors capability of fulfilling the requirement as it relates to the technical evaluation criteria. The price quote must include the price for the following line items: 1) Single Extracellular Vesicle Analysis from HANDLS participants. The Unique Entity ID from SAM.gov, the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All quotations must be received by 12:00pm Eastern Daylight Time, on August 6, 2024, and reference Solicitation Number 75N95024Q00482. Responses must be submitted electronically to Michele Pastorek, Contracting Officer at michele.pastorek@nih.gov. Fax responses will not be accepted.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:75N95024Q00482
  1. Combined Synopsis
  1. 2×
    Combined SynopsisCurrentJul 30, 2024

    Single Extracellular Vesicle Analysis from HANDLS participants.

    Notice 236b4401ef314a44b98aa9e74aab050d on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
THIS IS A SOURCES SOUGHT ANNOUNCEMENT ONLY. It is neither a solicitation announcement nor a request for proposals or quotes and does not obligate the Government to award a contract. Requests for a solicitation will not receive a response. Responses to this sources sought must be in writing. The purpose of this sources sought announcement is for market research to make appropriate acquisition decisions and to gain knowledge of potential qualified Small Businesses interested and capable of providing the services described below. NIH-OD-SS-27-000058 The information gained from this market research will help the National Institutes (NIH) Clinical Center (CC) plan for its acquisition strategy. Potential Large and Small Businesses shall include business information outlined in the section below as a part of their response. Complete responses to this notice shall be in the following format: SAM UEI Number and CAGE code Company Name Company Address, City, State and Zip Code Company Point of Contact, Email Address and Telephone Number Current GSA Schedule appropriate to this Sources Sought of other FAR Part 8 considerations Socioeconomic Status: (i.e., HUBZone, 8a, Small Business, Women Owned Small Business, Veteran-Owned Small-Business, etc.) https://www.sam.gov. Provide a capability statement that addresses the organizations qualifications and ability to perform as a contractor for the work described in the Statement of Work. The NIH Clinical Center Office of Research Support and Compliance (ORSC) is seeking a qualified and experienced contractor to provide project management and coordination of routine and emergent qualification, calibration/PM and certification services, including repairs and replacements, for the departments/ICs located at the NIH’s Bethesda, MD campus. Please see attached SOW for more details. Contractors shall not reach out to the customer for any questions or clarifications. All communications must go through contracting. ****************************************************************************** Important information: The Government is not obligated to nor will it pay for or reimburse any costs associated with responding to this source sought synopsis request. This notice shall not be construed as a commitment by the Government to issue a solicitation or ultimately award a contract, nor does it restrict the Government to a particular acquisition approach. The Government will in no way be bound to this information if any solicitation is issued. No sub-contracting opportunity is anticipated. NAICS: The North American Classification System (NAICS) code for this acquisition is 541380. PSC: H966 Notice to potential offerors: All offerors who provide goods or services to the United States Federal Government must be registered and have an active registration in the System for Award Management (SAM) at www.sam.gov and complete Online Representations and Certifications Application (ORCA). All interested Offerors should submit information by e-mail to ryssa.nix@nih.gov. Please use subject line “Response to NIH-OD-SS-27-000058”. All information submissions shall be received no later than noon on November 15, 2026.
-Pre-Solicitation11/15/2026
INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to: Alcami Corporation 2320 Scientific Park DR Wilmington, North Carolina 28405-1800 NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 541380 with a Size Standard $16.6M. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2026-01, March 13, 2026. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($350,000). STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. GENERAL INFORMATION Title: Stability Testing for ManNAc Drug Product produced in Campaigns 5 and 6. Stability testing will occur under regulatory compliance Background Information: NHGRI was gifted 48kg of unlabeled drug ManNAc (powder-in-sachet) in September 2025, and agreed to take over the FDA-required, mandatory, stability testing program of this drug that has been ongoing at Alcami Corporation since June 2024. The gifted drug was produced in 2 campaigns, Campaign 5 (C5, June 2024) and Campaign 6 (C6, September 2024). NHGRI plans to use the donated clinical grade drug for upcoming clinical trials. CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, the period of performance, the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by November 9, 2026 at 9:00 AM Eastern time and must reference solicitation number 75N98027Q00040. Responses may be submitted electronically to Mr. James Law, Contracting Officer at James.Law@nih.gov. Fax responses will not be accepted. "All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.”
-Pre-Solicitation11/09/2026
Please see attached Sources Sought. Questions & Answers attached.
-Market Research11/12/2026
Centers for Disease Control (CDC) is issuing this synopsis as a means of conducting market research to identify parties having an interest in and the resources to support this requirement for a California-based integrated health care system to serve as an electronic health record site in CDC’s VISION 2.0 respiratory pathogen surveillance network, providing integrated, longitudinal medical, laboratory, pharmacy, vaccination, claims, and outcomes data to support influenza surveillance, vaccine-effectiveness studies, and related respiratory pathogen research across emergency/urgent care, inpatient, and intensive care unit (ICU) settings. The result of this market research will contribute to determining the method of acquisition. The applicable North American Industry Classification System (NAICS) code assigned to this acquisition is 541380- Testing Laboratories and Services.
-Market Research12/04/2026
The vendor shall provide the license for the updated ABAQUS software. The vendor shall also provide technical support if/when needed throughout the year. If there are any issues with software the vendor shall provide fix. ABAQUS is approved in the CDC SRT tool.
-Special Notice07/20/2027

Additional Details

Solicitation Number

75N95024Q00482

Archive Date

Aug 21, 2024

Place of Performance Country

GBR

Office Address

Bethesda, MD, 20892